H A Wakelee1, A Patnaik2, B I Sikic3, M Mita2, N L Fox4, R Miceli4, S J Ullrich4, G A Fisher3, A W Tolcher2. 1. Department of Medicine-Oncology, Stanford University, Stanford, CA. Electronic address: hwakelee@stanford.edu. 2. Department of Clinical Research, Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX. 3. Department of Medicine-Oncology, Stanford University, Stanford, CA. 4. Human Genome Sciences, Rockville, MD, USA.
Abstract
BACKGROUND: Lexatumumab (HGS-ETR2) is a fully human agonistic mAb to the tumor necrosis factor-related apoptosis-inducing ligand receptor 2 that activates the extrinsic apoptosis pathway and has potent preclinical antitumor activity. MATERIALS AND METHODS: This phase 1, dose escalation study assessed the safety, tolerability, pharmacokinetics (PKs) and immunogenicity of lexatumumab administered i.v. every 14 days in patients with advanced solid tumors. RESULTS: Thirty-one patients received lexatumumab over five dose levels (0.1-10 mg/kg). Most (26 of 31) received four or more cycles of treatment. One patient at 10 mg/kg experienced a possibly related dose-limiting toxicity of grade 3 hyperamylasemia. Nine patients achieved stable disease. One patient with chemotherapy-refractive Hodgkin's disease experienced a mixed response. Lexatumumab PKs were linear up to 10 mg/kg. At the 10 mg/kg dose, the mean (+/-standard deviation) t(1/2b) was 13.67 +/- 4.07 days, clearance was 4.95 +/- 1.93 ml/day/kg, V(1) was 45.55 ml/kg and V(ss) was 79.08 ml/kg, indicating that lexatumumab distributes outside the plasma compartment. No human antihuman antibodies were detected. CONCLUSIONS: Lexatumumab can be safely administered every 14 days at 10 mg/kg. The PK profile supports this schedule. Further evaluation of lexatumumab at this dose schedule is warranted, including combination trials with other agents.
BACKGROUND:Lexatumumab (HGS-ETR2) is a fully human agonistic mAb to the tumor necrosis factor-related apoptosis-inducing ligand receptor 2 that activates the extrinsic apoptosis pathway and has potent preclinical antitumor activity. MATERIALS AND METHODS: This phase 1, dose escalation study assessed the safety, tolerability, pharmacokinetics (PKs) and immunogenicity of lexatumumab administered i.v. every 14 days in patients with advanced solid tumors. RESULTS: Thirty-one patients received lexatumumab over five dose levels (0.1-10 mg/kg). Most (26 of 31) received four or more cycles of treatment. One patient at 10 mg/kg experienced a possibly related dose-limiting toxicity of grade 3 hyperamylasemia. Nine patients achieved stable disease. One patient with chemotherapy-refractive Hodgkin's disease experienced a mixed response. Lexatumumab PKs were linear up to 10 mg/kg. At the 10 mg/kg dose, the mean (+/-standard deviation) t(1/2b) was 13.67 +/- 4.07 days, clearance was 4.95 +/- 1.93 ml/day/kg, V(1) was 45.55 ml/kg and V(ss) was 79.08 ml/kg, indicating that lexatumumab distributes outside the plasma compartment. No human antihuman antibodies were detected. CONCLUSIONS:Lexatumumab can be safely administered every 14 days at 10 mg/kg. The PK profile supports this schedule. Further evaluation of lexatumumab at this dose schedule is warranted, including combination trials with other agents.
Authors: Georgios V Georgakis; Yang Li; Robin Humphreys; Michael Andreeff; Susan O'Brien; Mamoun Younes; Antonino Carbone; Vivian Albert; Anas Younes Journal: Br J Haematol Date: 2005-08 Impact factor: 6.998
Authors: J P Sheridan; S A Marsters; R M Pitti; A Gurney; M Skubatch; D Baldwin; L Ramakrishnan; C L Gray; K Baker; W I Wood; A D Goddard; P Godowski; A Ashkenazi Journal: Science Date: 1997-08-08 Impact factor: 47.728
Authors: Jan J Koornstra; Mathilde Jalving; Fleur E M Rijcken; Jantine Westra; Nynke Zwart; Harry Hollema; Elisabeth G E de Vries; Robert W M Hofstra; John T M Plukker; Steven de Jong; Jan H Kleibeuker Journal: Eur J Cancer Date: 2005-05 Impact factor: 9.162
Authors: Larisa L Belyanskaya; Thomas M Marti; Sally Hopkins-Donaldson; Stefanie Kurtz; Emanuela Felley-Bosco; Rolf A Stahel Journal: Mol Cancer Date: 2007-10-22 Impact factor: 27.401
Authors: Sunil Sharma; Elisabeth G de Vries; Jeffrey R Infante; Corina N Oldenhuis; Jourik A Gietema; Lin Yang; Sanela Bilic; Katie Parker; Michael Goldbrunner; Jeffrey W Scott; Howard A Burris Journal: Invest New Drugs Date: 2013-04-16 Impact factor: 3.850